Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine

Biotechnology and Bioprocess Engineering

Volumn 7, Issue 6, 2002, Pages 340-346

  Kim, In Seop ^a   Choi, Yong Woon ^a   Lee, Sung Rae ^a   Kang, Yong ^a   Lee, Kyung Myung ^b   Park, Dae Han ^b   Woo, Han Sang ^a   Lee, Soungmin ^a  

^a Green Cross Plasma Derivatives Company

^b Green Cross Company   (South Korea)

Author keywords

Hepatitis A virus; Inactivation; Log reduction factor; Removal; Urokinase

Indexed keywords

EID: 33644781314     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02933518     Document Type: Article

References (28)

1. Sherry, S. (1987) Thrombolytic therapy in acute myocardial infarction. A perspective. Drugs 33 (Suppl 3): 1-12.
2. Coulepis, A. G., S. A. Locarnini, N. I. Lehmann, and I. D. Gust (1980) Detection of hepatitis A virus in the feces of patients with naturally acquired infections. J. Infect. Dis. 141: 151-156.
3. Andrewes, C. (1989) Andrewes' Viruses of Vertebrates, pp. 120-145. Balliere Tindal, London, UK.
4. Borovec, S., C. Broumis, W. Adcock, R. Fang, and E. Uren (1998) Inactivation kinetics of model and relevant bloodborne viruses by treatment with sodium hydroxide and heat. Biologicals 26: 237-244.
5. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee (2001) Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73.
6. Mosley J. W and J. Rakela (1999) Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044.
7. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95).
8. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Availability. Federal Resister 63(185): 51074-51084.
9. Kim, I. S., Y. W. Choi, H. S. Woo, C. E. Chang, and S. Lee (2000) Solvent/detergent inactivation and chromatographic removal of human immunodeficiency virus during the manufacturing of a high purity antihemophilic factor VIII concentrate. J. Microbiol. 38: 187-191.
10. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30.
11. Han, B., J. O. Carlson, S. M. Powers, and S. R. Wickramasinghe (2002) Enhanced virus removal by flocculation and microfiltration. Biotechnol. Bioprocess Eng. 7: 6-9.
12. Kim, I. S., Y. W. Choi, S. R. Lee, H. B. Cho, H. G. Eo, H. S. Woo, C. E. Chang, and S. Lee (2001) Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation. J. Microbiol. Biotechnol. 11: 619-627.
13. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety: Part 1. General considerations. Bio. Pharm. February: 32-43.
14. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503.
15. Hamman, J., J. Zou, and B. Horowitz (1994). Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates. Vox Sang. 67 (Suppl. 1): 72-77.
16. Lemon, S. M., P. C. Murphy, A. Smith, J. Zou, J. Hammon, S. Robinson, and B. Horowitz (1994) Removal/ neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. J. Med. Virol. 43: 44-49.
17. Adcock, W. L., A. Macgregor, J. R. Davies, M. Hattarki, D. A. Anderson, and N. H. Goss (1998) Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin. Biotechnol. Appl. Biochem. 28: 85-94.
18. Arahana, H. (2001) Viral clearance strategies for biopharmaceutical safety. Part 2: Filtration for viral clearance. Bio. Pharm. February: 32-43.
19. Aranha-Creado, H., J. Peterson, and P. Y. Huang (1998) Clearance of murine leukaemia virus from monoclonal antibody solutions by a hydrophilic PVDF microporous membrane filter. Biologicals 26: 167-172.
20. Eibl, J., N. Barrett, T. Hammerle, and F. Dorner (1996) Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV Biologicals 24: 285-287.
21. Graf, E. G., E. Jander, A. West, H. Pora, and H. Aranha-Creado (1999) Virus removal by filtration. Dev. Biol. Stand. 99: 89-84.
22. Oshima, K. H., T. T. Evans-strickfaden, and A. K. Highsmith (1998) Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter. Vox Sang. 75: 181-188.
23. Oshima, K. H., T. T. Evans-strickfaden, A. K. Highsmith, and E. W. Ades (1998) The use of a microporus polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins. Biologicals 24: 137-145.
24. Roberts, P. (1997) Efficient removal of viruses by a novel polyvinylidene fluoride membrane filter. J. Virol. Methods 65: 27-31.
25. Troccoli, N., J. Mclver, A. Losikoff, and J. Poiley (1998) Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 26: 321-329.
26. Kim, I. S., H. G. Eo, C. E. Chang, and S. Lee (2000) Partitioning and inactivation of viruses by cold ethanol fractionation and pasteurization during manufacture of albumin from human plasma. J. Microbiol. Biotechnol. 10: 858-864.
27. Heimburger, N. and H. E. Karges (1989) Strategies to produce virus-safe blood derivatives. Curt Stud. Hematol. Blood Transfus. 56: 23-33.
28. Nowak, T., M. Niedrig, D. Bernhardt, and J. Hilfenhaus (1993) Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization. Dev. Biol. Stand. 81: 169-176.